Latest Articles

Publication Date
Circulating miRNA as diagnostic tools for gynecological diseases and their applications in biosensor development.

MicroRNAs (miRNAs) have emerged as robust biomarkers for diagnosing and prognosing gynecological diseases due to their disease-specific expression and remarkable stability in body fluids. Despite the inherent instability of RNA …

Published: Nov. 15, 2025, midnight
FDA approves Promega’s OncoMate test to guide personalised treatment for endometrial cancer - Indian Pharma Post

FDA approves Promega’s OncoMate test to guide personalised treatment for endometrial cancer Indian Pharma Post

Published: Nov. 14, 2025, 3:26 p.m.
Metabolomics reveals the therapeutic efficacy of liposomal resvida in endometrial cancer through regulating autophagy-related gene expression - Cancer Cell International

Metabolomics reveals the therapeutic efficacy of liposomal resvida in endometrial cancer through regulating autophagy-related gene expression Cancer Cell International

Published: Nov. 14, 2025, 4:25 a.m.
Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 - Quiver Quantitative

Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 Quiver Quantitative

Published: Nov. 13, 2025, 9:25 p.m.
Insufficient Endometrial Biopsy Increases Cancer Risk - European Medical Journal

Insufficient Endometrial Biopsy Increases Cancer Risk European Medical Journal

Published: Nov. 13, 2025, 1:03 p.m.
FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer - Voice Of HealthCare

FDA Approves Promega OncoMate® MSI Dx as Companion Diagnostic for KEYTRUDA® and LENVIMA® in Endometrial Cancer Voice Of HealthCare

Published: Nov. 13, 2025, 6:17 a.m.
FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma - 뉴스와이어

FDA Approves Promega OncoMate® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA® in Combination with LENVIMA® In Advanced Endometrial Carcinoma 뉴스와이어

Published: Nov. 13, 2025, 5:50 a.m.
N6-methyladenosine regulated FZD7 inhibits ferroptosis in endometriosis via β-catenin/SLC7A11 pathway.

Endometriosis (EMS), a chronic inflammatory disease affecting approximately 10% reproductive aged women, remains etiologically unclear. This study aims to investigate the role and underlying mechanisms of frizzled class receptor 7 …

Published: Nov. 13, 2025, midnight
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer - CancerNetwork

FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer CancerNetwork

Published: Nov. 12, 2025, 7:12 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!